Disciplines:
  • Nursing
  • Advanced Practice Nursing
  • Hours: 3 Contact Hours
    (3 Pharm Hours)
    Author(s): Diana M. Sobieraj, PharmD, BCPS
    Peer Reviewer(s):
  • Leanne Henry Fowler, DNP, AGACNP-BC, CCRN, CNE
  • Amy Drew, PharmD, BCPS
  • Item#: N1718
    Contents: 1 Course Book (44 pages)

    Oral Anticoagulant Therapy: Implications for Patient Management



    Price $19.95
    Item # N1718
    New
    When available, the Online Course format is included with the hard copy, eBook, or audio book formats!

    Release Date: August 25, 2016

    Expiration Date: August 31, 2019

    Oral anticoagulants are indicated for the management of thrombotic conditions, namely, in the prevention of stroke and systemic embolization and in the treatment of venous thromboembolism. Within the past 6 years, the landscape of managing these conditions in the United States has changed dramatically. The FDA has approved four oral anticoagulants representing alternatives to the gold standard oral anticoagulant warfarin that had been the only oral option for decades.
     
    The focus of this course is on the newest oral anticoagulant drug therapies, their indications, and data supporting their use in clinical practice. This course is designed for advanced practice nursing prescribers who are involved in the decision making for oral anticoagulant selection; or who take care of patients who have already been prescribed oral anticoagulants. The purpose of this course is to increase advanced nursing prescribers’ knowledge of oral anticoagulants to identify patients in whom therapy is indicated, to assist in selecting the most appropriate option, and to assist in appropriate monitoring and counseling the patient.

     

    Course Objectives
    • Identify oral anticoagulants, their respective pharmacologic class, and their approved indications.
    • Examine the current place in therapy of oral anticoagulants in the management of patients with atrial fibrillation and in prevention and treatment of venous thromboembolism (VTE).
    • Describe evidence supporting the use of oral anticoagulants in patients with atrial fibrillation and in the prevention and treatment of VTE.
    • Identify pertinent contraindications, side effects, drug interactions, monitoring parameters, and patient counseling points for oral anticoagulants.
    • Identify reversal agents for oral anticoagulants.

    Diana M. Sobieraj, PharmD, BCPS, earned her Doctor of Pharmacy degree from the University of Rhode Island and subsequently completed a pharmacy practice residency at Hartford Hospital/The University of Connecticut School of Pharmacy. After her training, Dr. Sobieraj joined the faculty at UCONN School of Pharmacy, where she has worked for the past 8 years. Currently, Dr. Sobieraj is an Assistant Professor in the Department of Pharmacy Practice in the tenure track. Her scholarly interests focus on comparative effectiveness and health outcomes research of anticoagulants and the treatment and prevention of thrombosis. Dr. Sobieraj has more than 40 publications in the peer-reviewed literature, including journals such as Annals of Internal Medicine, Journal of the American Geriatrics Society, International Journal of Cardiology, and Thrombosis Research. Dr. Sobieraj is a member of the American College of Clinical Pharmacy, the current Secretary/Treasurer of the American College of Clinical Pharmacy Health Outcomes PRN, and a member of the Community Advisory Panel of the American College of Clinical Pharmacy Practice-Based Research Network.

    Leanne Henry Fowler, DNP, AGACNP-BC, CCRN, CNE, graduated with a baccalaureate of science in nursing degree from Southern University in Baton Rouge, Louisiana, and a doctorate in nursing practice (DNP) specializing in nursing education and as an adult/gerontology acute care nurse practitioner from the University of South Alabama in Mobile. She conducted a successful quality improvement project for her DNP project titled Preventing Oversedation in the Mechanically Ventilated Adult via Interprofessional Implementation of the RASS Tool. She has 15 years of critical care nursing experience, 8 years of nursing education experience, 2 years as a board-certified adult/gerontology acute care nurse practitioner in hospital medicine, and 6 months in infectious diseases. She is ranked as an instructor at the LSU Health Sciences Center’s School of Nursing, where she is the course coordinator for the critical care course in the baccalaureate program and the BSN to DNP academic coordinator for the Adult-Gerontology Acute and Emergency Care Nurse Practitioner concentration. She is an active member in several professional organizations, including the American Association of Nurse Practitioners (nationally, as well as in the state and local chapters), American
    Association of Critical-Care Nurses (nationally, as well as the local chapter), Society of Critical Care Medicine (nationally, as well as the regional chapter), National League for Nursing, National Organization of Nurse Practitioner Faculty, and the Epsilon Nu chapter of Sigma Theta Tau.

    Amy Drew, PharmD, BCPS, is an Associate Professor with the Division of Pharmacy Practice, Preceptor for PGY 1 Pharmacy Residency Program at Mercy Hospital/Saint Louis College of Pharmacy in Saint Louis, Missouri, and Clinical Pharmacist in Ambulatory Care at Mercy Clinic Family Medicine in Saint Louis, Missouri. Dr. Drew earned her earned her BS in Biology from University of Illinois at Urbana-Champaign and her PharmD from Midwestern University in Glendale, Arizona. She completed her residency training at the John Cochran VA Medical Center in St. Louis, Missouri. Since then, she has had a full-time faculty appointment with responsibilities in teaching, lecture coordination, resident and student precepting, research, and clinical practice. Her practice and scholarship have focused primarily in the areas of anticoagulation, diabetes, osteoporosis, and teaching and learning within the advanced practice setting. She is an active member of the American College of Clinical Pharmacy and American Society of Health-Systems Pharmacists, and she is board certified in pharmacotherapy specialty.

     

    • Contact hours will be awarded for up to one (1) year from date of purchase or by the expiration date indicated above, whichever date comes first.
    • You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
    • Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support.
    • All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.